The same study also showed that resistant melanomas possess low MITF expression, but high levels of inflammatory nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NF-ĸB) signaling and the receptor tyrosine kinase (RTK) AXL [18]. This evidence concerns the gene MITF and melanoma.